Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 8, 2021
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
[ Mon, Mar 08th 2021
] - WOPRAI
Ed Arce Maintained (AKBA) at Strong Buy with Decreased Target to $6 on, Mar 8th, 2021
Ed Arce of HC Wainwright & Co., Maintained "Akebia Therapeutics, Inc." (AKBA) at Strong Buy with Decreased Target from $9 to $6 on, Mar 8th, 2021.
Ed has made no other calls on AKBA in the last 4 months.
There is 1 other peer that has a rating on AKBA. Out of the 1 peers that are also analyzing AKBA, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Eric Joseph of "JP Morgan" Downgraded from Hold to Sell on, Friday, January 29th, 2021
